

Ines De Pauw

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8602155/publications.pdf>

Version: 2024-02-01

12
papers

209
citations

1039406

9
h-index

1199166

12
g-index

12
all docs

12
docs citations

12
times ranked

350
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma. <i>Medicinal Research Reviews</i> , 2022, 42, 112-155.	5.0	24
2	The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy. <i>Frontiers in Oncology</i> , 2021, 11, 697967.	1.3	11
3	The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chaperoning Immunotherapeutic Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 737311.	2.2	28
4	Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib. <i>Cancers</i> , 2019, 11, 98.	1.7	10
5	<i>In vitro</i> study of the Polo-like kinase 1 inhibitor volasertib in non-small cell lung cancer reveals a role for the tumor suppressor p53. <i>Molecular Oncology</i> , 2019, 13, 1196-1213.	2.1	17
6	Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. <i>Cancers</i> , 2019, 11, 1893.	1.7	7
7	Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. <i>Molecular Oncology</i> , 2018, 12, 830-854.	2.1	36
8	Enzymes Catalyzing the TCA- and Urea Cycle Influence the Matrix Composition of Biofilms Formed by Methicillin-Resistant <i>Staphylococcus aureus</i> USA300. <i>Microorganisms</i> , 2018, 6, 113.	1.6	21
9	Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 229-238.	0.7	15
10	Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia. <i>Journal of Cancer</i> , 2017, 8, 1441-1452.	1.2	11
11	Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 229-238.	0.7	8
12	The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines. <i>BMC Research Notes</i> , 2015, 8, 203.	0.6	21